In a statement, Novo Nordisk said the rapprochement between the two companies is "a meaningful win for patients in the US" and will expand access to Ozempic and Wegovy, adding that the two products have been "evaluated for safety and efficacy." The company also said that it "welcomes Hims & Hers shifting their GLP-1 business model to focus on increasing access to affordable, branded FDA-approved medicines." It has also agreed to drop its lawsuit with Hims & Hers that followed the compounded oral semaglutide announcement
Yes, resting heart rate typically returns to near-baseline within weeks after stopping semaglutide, as your metabolism stabilizes and weight loss plateaus
Its receptor selectivity and well-characterized structure make it useful in experimental models evaluating peptide-mediated signaling mechanisms under controlled research conditions
Manufacturing these medicines involves living cells, precision engineering, and strict quality controls
These medications change how your body handles hunger, digestion, and fullness, so coming off them too quickly can be a big shift